Serologic evaluation of Celiac disease in patients with Beta thalassemia major and control
Gastroenterology and Hepatology from Bed to Bench,
Vol. 8 No. 2 (2015),
17 Esfand 2015
,
Page Gastroenterol Hepatol Bed Bench 2015;8(2):153-159
https://doi.org/10.22037/ghfbb.v8i2.717
Abstract
Abstract
Introduction: Celiac Disease (CD) is an autoimmune disorder triggered by ingestion of gluten in genetically predisposed individuals. This study reports evaluated prevalence of CD in patients with Beta-thalassemia major.
Materials and Methods: In this case-control study in a period of 3 years which was performed on 620 children in two groups of Beta-thalassemia major patients (n=200) and control (n=420), serum Tissue Transglutamianse (TTG) IgA levels were measured. The two groups were compared together in terms of TTG IgA levels, and p<0.05 was considered significant.
Results: The means of serum TTG IgA levels in patients with Beta-thalassemia major and control groups were 28.81±68.44 and 6.94±6.68 U/mL, respectively, there was a significant difference in favor of the case group (p=0.000). Body mass index in the two case and control groups had a significant difference (t=3.859, p=0.001). Belonging to each group will change the probability of having less than 20 in TTG IgA (odds=0.285) and it means that belonging to the control group has a protective role. There is only a significant association in the case of all population (r=0.102, p=0.011). Body mass index in the two case and control groups had a significant difference (t=3.859, p=0.001).
Discussion: Probability of CD should be considered since the prevalence of CD is high in patients with and Beta-thalassemia major. Patients with thalassemia major are recommended to be screened for CD.
Keywords: Celiac disease, Beta-thalassemia major, Growth disorder, Disease risk, HLA
- Celiac disease
- Beta-thalassemia major
- Growth disorder
- Disease risk
- HLA
How to Cite
- Abstract Viewed: 229 times
- PDF () Downloaded: 148 times